Terrance J. Coughlin has been named chief operating officer of Par Pharmaceutical Companies, Inc. Mr. Coughlin will be responsible for global manufacturing activities and R&D efforts, as well as the new product selection process. 
 
Mr. Coughlin joins the company from Glenmark Generics, Inc., where he most recently served as president and chief executive officer, and prior to that, served as president. Mr. Coughlin had overall responsibility for the North American, Western European and Eastern European generics businesses, as well as the global API business and generics operations in India. Mr. Coughlin also served as senior vice president at Dr. Reddy’s Laboratories, and was responsible for global key accounts for bulk active ingredient operations for North America and Europe. 
 
“Having worked with Terry, I know personally that he is a talented and capable senior manager with a proven track record of success,” said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies. “Terry’s more than 25 years experience in the pharmaceutical industry extends from API to finished dosage, and from R&D to sales and marketing.  He has managed businesses, including manufacturing facilities, in the U.S. and abroad.  Terry’s breadth of experience will serve Par well and I am excited to welcome him to our company.”